TECX

20.7301.47%
AS

Alise S. Reicin

President, CEO, Secretary & Director

Dr. Alise S. Reicin, MD, PhD, serves as Member of Strategic Advisory Board at SCTbio a.s. (formerly known as Sotio a.s.). since November 2021. She serves on the board of directors of Sana Biotherapeutics and Sharsheret. She serves as Non-executive director at Immatics N.V. since July 29,2024. Dr. Reicin has extensive early and late clinical development experience working across a broad range of therapeutic areas. She played a leadership role which led to the initial approval of 10 novel medicines and the approval of >10 indications for an additional five drugs. Dr. Reicin served as Vice President, Oncology at Merck. She has been Secretary at Tectonic Therapeutic, Inc. and serves as its Director since August 2020. She serves as Independent Director of Sana Biotechnology, Inc. since December 2020. Dr. Reicin serves as Chief Executive Officer and President of Tectonic Therapeutic, Inc. since August 2020. Dr. Reicin has been Director of Homology Medicines, Inc since July 15, 2019. Dr. Reicin had been President of Global Clinical Development at Celgene Corporation since November 1, 2018 until December 2019, where she oversaw the development and approval of drugs across their pipeline in Oncology, Hematology and Autoimmune diseases and Fibrosis. Dr. Reicin served as Senior Vice President and Head of Global Clinical Development of Biopharma of Merck KGaA until November 1, 2018. Dr. Reicin was Head of Global Clinical Development and Senior Vice President at EMD Serono, Inc. since May 11, 2015 until October 2018. Dr. Reicin was Head of Global Clinical Development and Senior Vice President at Merck Serono S.A. since April 2015. Dr. Reicin served as Vice President of Project and Pipeline Leadership, Oncology Franchise at MSD. In this capacity, she led MSD's PD-1 program and oversaw the initial development and filing activities worldwide, including the first approval in the US. Dr. Reicin also managed program leaders across early and late oncology product development teams. During her tenure at MSD, she held roles of increasing responsibility in R&D, including Vice President and Therapeutic Area Head (Bone, Respiratory, Immunology and Endocrinology); Vice President, Research & Early Development (Bone, Respiratory, Immunology and Endocrinology Franchise Integrator); Vice President, Strategic Realization Office; Vice President and Therapeutic Area Head (Clinical Immunology & Analgesia); and Head of a Transformation Task Force for late clinical development. Before joining MSD, Dr. Reicin was a Faculty Member at Columbia Medical School and a Physician and Researcher at Columbia Presbyterian Hospital. Dr. Reicin holds B.A. in biochemistry from Barnard College of Columbia University and received her M.D. in Medicine from Harvard Medical School, where she was enrolled in the Health Sciences and Technology program with MIT.

Positions